Search
Gedivumab
go.drugbank.com/drugs/DB15277InvestigationalGedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).
Gimsilumab
go.drugbank.com/drugs/DB15280InvestigationalGimsilumab is under investigation in clinical trial NCT01357759 (Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects).
Setogepram
go.drugbank.com/drugs/DB15447InvestigationalSetogepram is under investigation in clinical trial NCT03184584 (Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome).
YCT-529
go.drugbank.com/drugs/DB21748InvestigationalYCT-529 is under investigation in clinical trial NCT06542237 (Open Label, Repeat Dose Study Evaluating YCT-529 in Healthy Males).
Atigotatug
go.drugbank.com/drugs/DB14831InvestigationalIt is under investigation in clinical trial NCT02815592 (Trial of BMS-986012 in Combination With Platinum and Etoposide).
ISO-1 F-18
go.drugbank.com/drugs/DB14900InvestigationalISO-1 F-18 is under investigation in clinical trial NCT00968656 (Assessment of Cellular Proliferation in Tumors by Positron Emission Tomography (PET) Using [18F]ISO-1).
Milciclib Maleate
go.drugbank.com/drugs/DB16232InvestigationalMilciclib Maleate is under investigation in clinical trial NCT01301391 (Study of Oral PHA-848125AC in Patients With Malignant Thymoma Previously Treated With Multiple Lines of Chemotherapy).
GS-100
go.drugbank.com/drugs/DB18337InvestigationalGS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence
Ziltivekimab
go.drugbank.com/drugs/DB18836InvestigationalZiltivekimab is under investigation in clinical trial NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation).
Mapatumumab
go.drugbank.com/drugs/DB18945InvestigationalMapatumumab is under investigation in clinical trial NCT00094848 (Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-hodgkin's Lymphoma (NHL)).